Results from the phase 2 clinical trial DESTINY-Breast01 showed that the investigational human epidermal growth factor receptor 2 (HER2)-targeted antibody-drug conjugate [Fam-] trastuzumab deruxtecan (T-DXd) has durable objective responses in patients with HER2-positive breast cancer who were heavily pretreated. Although T-DXd had a generally manageable safety profile, interstitial lung disease (ILD) was identified as a risk warranting proactive awareness and management.
Despite the fact that HER2-directed therapies like trastuzumab, pertuzumab, and T-DM1 have led to improved outcomes for patients with HER2-positive advanced breast cancer, resistance to these drugs is almost inevitable. Once patients develop resistance, it is not clear what treatment should be given, highlighting the unmet medical need for new and improved therapies for these patients. T-DXd is an antibody-drug conjugate with an HER2 antibody, peptide-based cleavable linker, and a novel topoisomer...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Partial breast irradiation could be as effective as whole breast irradiation Next Article
Neoadjuvant + adjuvant pembrolizumab improves pCR in triple-negative breast cancer with lymph node involvement »
Table of Contents: SABCS 2019
Screening, Detection, and Diagnosis
Phase 2 Trial Update
Phase 3 Trial Update
Long-Term Study Results
Triple-Negative Breast Cancer
HER2-Positive Breast Cancer
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.